What is the recommended management for an active miscarriage?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases Adjunctive therapy in the management of incomplete or inevitable abortion.

The recommended management for an active miscarriage may include oxytocin infusion as an adjunctive therapy in the management of incomplete or inevitable abortion. The dosage and administration of oxytocin for this indication are described in the drug label 1 and 1.

  • Intravenous infusion with physiologic saline solution or 5% dextrose in physiologic saline solution to which 10 units of oxytocin have been added should be infused at a rate of 20 to 40 drops/minute.
  • However, curettage is generally considered primary therapy in the first trimester. In the second trimester, oxytocin infusion will often be successful in emptying the uterus, but other means of therapy may be required in such cases.

From the Research

For an active miscarriage, the most effective management approach is medical management with misoprostol, as it is more effective than expectant management for complete evacuation of the uterus, with a success rate of 66% within 10 days, as shown in the study by 2. This approach uses medications to expedite the process, with the most effective regimen being misoprostol 800mcg vaginally or buccally, repeated if needed after 24 hours. The choice between medical, expectant, or surgical management depends on patient preference, gestational age, bleeding severity, infection risk, and medical history. Some key points to consider include:

  • Medical management with misoprostol is associated with more pain than expectant management, but it is a safe and effective option, as reported in the study by 2.
  • Expectant management involves waiting for the miscarriage to complete naturally without intervention, which may take 2-6 weeks but avoids procedure risks, as discussed in the study by 3.
  • Surgical management involves vacuum aspiration or dilation and curettage (D&C), which provides the quickest resolution and tissue confirmation but carries procedural risks, as mentioned in the study by 4. Patients should be monitored for complications including heavy bleeding, signs of infection, or persistent pain, and follow-up should include pregnancy testing 2-4 weeks after treatment to confirm complete expulsion of pregnancy tissue, as recommended in the study by 5. Each approach has similar long-term outcomes regarding future fertility, though surgical management offers the most rapid resolution, as noted in the study by 6. It is essential to provide detailed counseling to empower patients to make educated decisions about their management, considering the type of miscarriage and its influence on the relative success rates of each treatment option, as emphasized in the study by 5.

References

Research

Misoprostol treatment vs expectant management in women with early non-viable pregnancy and vaginal bleeding: a pragmatic randomized controlled trial.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2018

Research

[Management of first trimester miscarriages].

Journal de gynecologie, obstetrique et biologie de la reproduction, 2003

Research

The management of miscarriage.

Best practice & research. Clinical obstetrics & gynaecology, 2009

Research

Outcome of using vaginal misoprostol for treatment of retained products of conception after first trimester miscarriage: a retrospective cohort study.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.